Is Ablative Solutions ’ Latest Financing a Positive Sign for Renal Denervation?

Ablative Solutions latest financing might have just significantly improved investor faith in renal denervation procedures for the treatment of uncontrolled hypertension. The Kalamazoo, MI-based company revealed the first close of its $77 million series D round, which will be used to get its Peregrine System kit through regulatory trials. The firm’s device is a minimally invasive renal denervation technology designed to help reduce blood pressure for people with uncontrolled hypertension, while taking antihypertensive medication. The Peregrine System kit is engineered to target nerves known to influence the body’s regulation of blood pressure. The technology delivers dehydrated alcohol in small doses directly to the space outside of the renal artery to block the overactive signaling of the sympathetic nerves. “We have been supported the past few years by an amazing team of clinicians who, along with our very hard-working team, are committed to making this treatment available to patients,” Ablative Solutions’ CEO and CMO Tim Fischell, M.D., said in a release “We are excited to have the support of this thoughtful and high-powered group of investors, which will allow the company to complete the studies required to seek regulatory approvals in Europe and in the U.S.” MD&M West is where serious professionals find the technologies, education, and connecti...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news